BioCryst posts bigger Q2 revenue, profit on strong demand for skin disease drug ORLADEYO

BioCryst Pharmaceuticals

04/08/2025 12:13

Overview

BioCryst Q2 2025 ORLADEYO net revenue rises 45% y-o-y to $156.8 mln

Operating profit jumps 239% y-o-y to $29.8 mln, non-GAAP profit up 160%

Co makes $50 mln debt paydown, plans to retire remaining term debt with proceeds of sale of European business of skin disease drug ORLADEYO

Outlook

BioCryst maintains 2025 ORLADEYO revenue guidance at $580 mln to $600 mln

Company expects 2025 non-GAAP operating expenses of $440 mln to $450 mln

BioCryst anticipates positive cash flow and net income for full year 2025

Company plans to update expense guidance post-European business sale

Result Drivers

ORLADEYO REVENUE GROWTH - Driven by record new patient prescriptions and increased prescriber base

REAL-WORLD DATA IMPACT - Reinforced ORLADEYO's value, particularly for HAE patients with normal C1 inhibitor

U.S. MARKET CONTRIBUTION - U.S. sales accounted for 89.5% of global ORLADEYO revenues

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
$163.35 mln
Q2 EPS
$0.02
Q2 Net Income
$5.08 mln
Q2 Operating Expenses
$133.57 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for BioCryst Pharmaceuticals Inc is $15.00, about 47% above its August 1 closing price of $7.95

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 1,497 three months ago

Press Release: ID:nGNX8R9Sx8

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)